-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 25, Zai Lab announced that the Hong Kong Department of Health had approved the registration application of Ziller® (Nilapali) for the modification of registered pharmaceutical products for adult patients with advanced high-grade serous epithelial ovarian cancer to treat first-line platinum-containing products.
Maintenance treatment after chemotherapy has achieved complete remission or partial remission
.
Zele® is an oral poly(ADP-ribose) polymerase (PARP) inhibitor once a day
.
Unlike other PARP inhibitors that have been approved in Hong Kong, Zele® does not require BRCA mutation or other biomarker testing before medication
Note: The original text has been deleted